Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer

Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer

Invenra logoMADISON, Wis. (BUSINESS WIRE) Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer. Dr. Pereira brings more than 20 years of experience in oncology biologics drug discovery and development in biotech and pharma as a scientific leader, strategist, innovator, collaborator and fundraiser. His career efforts have led to the discovery and development of a range of FDA-approved drugs for patients with cancer.

β€œDan brings extensive experience in pre-clinical, translational and clinical development of I-O biologics and is an incredible asset for us,” Roland Green, Ph.D., Chief Executive Officer and Co-Founder of Invenra stated. β€œWe are excited to have Dan in this key role as Chief Scientific Officer and leverage his deep knowledge of I-O research and development as we advance our first-in-class I-O therapeutics programs and collaborative discovery efforts in oncology therapy.” This announcement represents a continuation of a buildout of management and capabilities at Invenra over the past 6 months, including the addition of a Chief Financial Officer, Timothy Daley, CPA.

Read more